The effect of low-dose interferon treatment on visual evoked potentials

Documenta Ophthalmologica

Volumn 94, Issue 3, 1997, Pages 215-221

  Moschos, Michael ^a,b   Manesis, Emanouel ^a   Panagakis, Efthimios ^a   Brouzas, Dimitrios ^a   Hadziyannis, Stephanos ^a   Theodossiadis, George ^a  

^a KAT HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Hepatitis B; Hepatitis C; Interferon alpha 2b; P100 implicit time; Visual evoked potentials

Indexed keywords

ALPHA2B INTERFERON;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DOSE RESPONSE; EVOKED VISUAL RESPONSE; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS HEPATITIS;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; EVOKED POTENTIALS, VISUAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; OPTIC NERVE; OPTIC NEURITIS; TREATMENT OUTCOME;

EID: 0031394314     PISSN: 00124486     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02582980     Document Type: Article

References (19)

1. German D, Schopfer K. Interferons. In: Dukes MNG (ed). Meyler's Side Effects of Drugs. Amsterdam: Elsevier Publishing Co, 1992: 746.
2. Janssen HLA, Brouwer JT, Nevens F, Sanchez-Tapias JM, Craxi A, Hadziyannis S. Fatal hepatic decompensation associated with interferon alpha. Br Med J 1993; 306: 107-8.
3. Vesikara T, Nuutila A, Cantell K. Neurologic sequelae following interferon therapy of juvenile laryngeal papilloma. Acta Paediatr Scand 1988; 77: 619-22.
4. Johnson DH, Hande KH, Hansworth JD, Greco FA. Neurotoxicity of interferons. Cancer Treat Rep 1983; 67: 958-61.
5. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41: 672-6.
6. Born J, Spath-Schwalbe E, Pietrowsky R, Porzolt F, Fehns HL. Neurophysiological effects of recombinant interferon-gamma and -alpha in man. Clin Physiol Biochem 1989; 7: 19-27.
7. Adams F, Fernandez F, Mavligit G. Interferon induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J Neuro Oncol 1988; 6: 355-9.
8. Iaffaioli RV, Fiorenza L, Davino M, Frasci G, LaMura G, Grossi D. Neurologic effects of long term treatment with low dose alpha 2b interferon. Curr Ther Res 1990; 48: 403-8.
9. Guyer DR, Tiereman J, Yannuzzi LA, et al. Interferon associated retinopathy. Arch Ophthalmol 1993; 111: 350-6.
10. Manesis M, Petrou C, Brouzas D, Hatziyannis S. Optic tract neuropathy complicating low-dose interferon treatment. J Hepatol 1994; 21: 474-7.
11. Fung WE. Interferon alpha 2a for treatment of age related macular degeneration. Am J. Ophthalmol 1991; 112: 349-50.
12. Chan CK, Kempin SJ, Noble SK, Palmer GA. The treatment of neovascular membranes by alpha interferon: an efficacy and toxicity study. Ophthalmology 1994; 101: 289-300.
13. Thomal MA, Ibanez HE. Interferon alpha-2a in the treatment of subfoveal choroidal neovascularization. Am J Ophthalmol 1993; 115: 563-8.
14. Poliner LS, Tornambe PE, Michelon PE, Heitzmann JG. Interferon alpha-2a for subfoveal neovascularization in age-related macular degeneration. Ophthalmology 1993; 100: 1417-24.
15. Pipkin FB. Medical statistics made easy. Edinburgh: Churchill Livingstone, 1984; 75.
16. bauherz G, Soeur M, Lustman F. Oculomotor nerve paralysis induced by alpha II-interferon. Acta Neurol Belg 1990; 90: 111-4.
17. Farkkila M, Iivanainen N, Roine R, et al. Neurotoxic and other side effects of high-dose interferon in amyotrophic lateral sclerosis. Acta Neurol Scand. 1984; 70: 42-6.
18. Quillen D, Zurlo J, Cunningham D, Blankenship G. Acute pigment epithelitis and hepatitis C. Am J Ophthalmol 1994; 118: 120-1.
19. Farkkila M, Iivanainen N. Neurotoxicity of interferon treatment. Read before the International Congress on Oncology, Espoo, Finland, June 1988.